Evaluation of nikkomycin Z with frequent oral administration in an experimental model of central nervous system coccidioidomycosis
<i>Coccidioides</i> species are endemic fungi that are capable of causing disease in patients with various comorbidities, as well as in otherwise healthy individuals. Treatment options for coccidioidomycosis are suboptimal, as azole antifungals may be limited by drug interactions and adverse effects due to interactions with enzymes found in humans and other mammals. Nikkomycin Z is an investigational agent that works against a target specific to the fungal cell wall (chitin), which is not present in the cells of humans or other mammals. In this study, we show that frequent oral administration of nikkomycin Z is effective in an experimental model of central nervous system coccidioidomycosis. Further studies of nikkomycin Z against coccidioidomycosis may be warranted.
Authors
- Thomas F. Patterson (ORCID: https://orcid.org/0000-0002-9513-7127)
- Laura K. Najvar
- Rosie Jaramillo
- Marcos Olivo
- Nathan P. Wiederhold (ORCID: https://orcid.org/0000-0002-2225-5122)
- David J. Larwood
Institutions
- The University of Texas at San Antonio Health Science Center (US)
Publication Details
- Journal
- Microbiology Spectrum
- Published
- 2024-08-20
- DOI
- https://doi.org/10.1128/spectrum.01356-24
- Citations
- 2
- Primary Topic
- Fungal Infections and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.77
Funders
- U.S. Department of Health and Human Services
- Gilead Sciences
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases